Pharma MarPHMMF -25.35%82 Buyback Yield % is 1.23 as of Jul. 02, 2026, which is 215% above its 10-year median of 0.39. GuruFocus rates PHMMF with a GF Score™ of 82/100 and a GF Value™ of $90.95 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 745 Biotechnology companies, Pharma Mar ranks better than 93.83% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Pharma Mar's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PHMMF vs VRTX, REGN, ALNY: Buyback Yield % Comparison
For the Biotechnology subindustry, Pharma Mar's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma Mar Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharma Mar's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Pharma Mar's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma Mar (PHMMF) has a Buyback Yield % of 1.23 as of Jul. 02, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Pharma Mar and its competitors. This is 215% above median its historical median of 0.39. According to the industry distribution chart, Pharma Mar ranks #46 out of 745 companies in the Biotechnology industry, placing it in the top 6.2%.
Is Pharma Mar's Buyback Yield % too high?
Pharma Mar's current Buyback Yield % of 1.23 is 215% above median its 10-year median of 0.39. Based on the distribution chart, Pharma Mar ranks #46 out of 745 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pharma Mar has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma Mar's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharma Mar ranks #46 out of 745 companies for Buyback Yield %. This places Pharma Mar in the top 6% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Pharma Mar and its competitors. Pharma Mar's current Buyback Yield % is 1.23, which is 215% above median its own 10-year median of 0.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Mar stock overvalued right now?
Based on GuruFocus' analysis, Pharma Mar (PHMMF) is currently considered Modestly Undervalued. The stock's GF Value™ is $90.95, compared to a current price of $79.49 — trading 12.6% below its estimated fair value. The current Buyback Yield % is 1.23, which is 215% above median its 10-year median of 0.39. Pharma Mar's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Pharma Mar (PHMMF), the current Buyback Yield % is 1.23 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma Mar (PHMMF) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma Mar stock appears to be undervalued.
The current stock price of $79.49 is trading 12.6% below its estimated GF Value™ of $90.95.
GuruFocus considers Pharma Mar to be Modestly Undervalued.
Key valuation signals for PHMMF:
Buyback Yield %: 1.23 (215% above median its 10-year median of 0.39)
GF Value™: $90.95 vs. price of $79.49 (12.6% below fair value)
No single metric tells the full story. See the PHMMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
82GF Score
Get the complete analysis for PHMMF
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHMMF has been successfully added to your 
